Ong’uti S, Czech M, Robilotti E, et al. Cefiderocol: a new cephalosporin stratagem against multidrug-resistant gram-negative bacteria. Clin Infect Dis. 2022;74(7):1303–12.

Article  CAS  PubMed  Google Scholar 

Giacobbe DR, Ciacco E, Girmenia C, et al. Evaluating cefiderocol in the treatment of multidrug-resistant gram-negative bacilli: a review of the emerging data. Infect Drug Resist. 2020;13:4697–711.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21(2):213–25.

Article  CAS  PubMed  Google Scholar 

Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18(12):1319–28.

Article  CAS  PubMed  Google Scholar 

Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226–40.

Article  CAS  PubMed  Google Scholar 

Timsit JF, Paul M, Shields RK, et al. Cefiderocol for the treatment of infections due to metallo-B-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 randomized studies. Clin Infect Dis. 2022;75(6):1081–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Falcone M, Tiseo G, Leonildi A, et al. Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2022;66(5): e0214221.

Article  PubMed  Google Scholar 

Falcone M, Tiseo G. Cefiderocol for the treatment of metallo-beta-lactamases producing gram-negative bacilli: lights and shadows from the literature. Clin Infect Dis. 2022;75(6):1085–7.

Article  PubMed  Google Scholar 

Bassetti M, Di Pilato V, Giani T, et al. Treatment of severe infections due to metallo-beta-lactamases-producing Gram-negative bacteria. Future Microbiol. 2020;3:1489–505.

Article  Google Scholar 

Zingg S, Nicoletti GJ, Kuster S, et al. Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: real-world Experience From a Case Series and Review of the Literature. Open Forum Infect Dis. 2020;7(6): ofaa185.

Article  PubMed  PubMed Central  Google Scholar 

Wicky PH, Poiraud J, Alves M, et al. Cefiderocol treatment for severe infections due to difficult-to-treat-resistant non-fermentative gram-negative bacilli in ICU patients: a case series and narrative literature review. Antibiotics (Basel). 2023;12(6):991.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Russo A, Bruni A, Gulli S, et al. Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19. Int J Antimicrob Agents. 2023;62(1): 106825.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rando E, Cutuli SL, Sangiorgi F, et al. Cefiderocol-containing regimens for the treatment of carbapenem-resistant A. baumannii ventilator-associated pneumonia: a propensity-weighted cohort study. JAC Antimicrob Resist. 2023;5(4): dlad085.

Article  PubMed  PubMed Central  Google Scholar 

Piccica M, Spinicci M, Botta A, et al. Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience. J Antimicrob Chemother. 2023;78(11):2752–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pascale R, Pasquini Z, Bartoletti M, et al. Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study. JAC Antimicrob Resist. 2021;3(4): dlab174.

Article  PubMed  PubMed Central  Google Scholar 

Palermo G, Medaglia AA, Pipito L, et al. Cefiderocol efficacy in a real-life setting: single-centre retrospective study. Antibiotics (Basel). 2023;12(4):746.

Article  CAS  PubMed  Google Scholar 

Meschiari M, Volpi S, Faltoni M, et al. Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections. JAC Antimicrob Resist. 2021;3(4): dlab188.

Article  PubMed  PubMed Central  Google Scholar 

Mazzitelli M, Gregori D, Sasset L, et al. Cefiderocol-based versus colistin-based regimens for severe carbapenem-resistant Acinetobacter baumannii infections: a propensity score-weighted, retrospective cohort study during the first two years of the COVID-19 pandemic. Microorganisms. 2023;11(4):984.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lupia T, Carnevale-Schianca F, Vita D, et al. Stenotrophomonas maltophilia infections in haematological malignancies and hematopoietic stem cell transplantation: a case series including cefiderocol-based regimens. Medicina (Kaunas). 2024;60(1):88.

Article  PubMed  Google Scholar 

Larcher R, Laffont-Lozes P, Roger C, et al. Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: a real-life study. Front Cell Infect Microbiol. 2022;12:1048633.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karruli A, Massa A, Andini R, et al. Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience. Int J Antimicrob Agents. 2023;61(2): 106723.

Article  CAS  PubMed  Google Scholar 

Hoellinger B, Simand C, Jeannot K, et al. Real-world clinical outcome of cefiderocol for treatment of multidrug-resistant non-fermenting, gram negative bacilli infections: a case series. Clin Microbiol Infect. 2023;29(3):393–5.

Article  CAS  PubMed  Google Scholar 

Giannella M, Verardi S, Karas A, et al. Carbapenem-resistant Acinetobacter spp infection in critically ill patients with limited treatment options: a descriptive study of cefiderocol therapy during the COVID-19 pandemic. Open Forum Infect Dis. 2023;10(7): ofad329.

Article  PubMed  PubMed Central  Google Scholar 

Gavaghan V, Miller JL, Dela-Pena J. Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections. Infection. 2023;51(2):475–82.

Article  CAS  PubMed  Google Scholar 

Fendian AM, Albanell-Fernandez M, Tuset M, et al. Real-life data on the effectiveness and safety of cefiderocol in severely infected patients: a case series. Infect Dis Ther. 2023;12(4):1205–16.

Article  PubMed  PubMed Central  Google Scholar 

Falcone M, Tiseo G, Nicastro M, et al. Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant gram-negative infections in intensive care unit patients. Clin Infect Dis. 2021;72(11):2021–4.

Article  CAS  PubMed  Google Scholar 

El Ghali A, Kunz Coyne AJ, Lucas K, et al. Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections. Microbiol Spectr. 2024;12(2): e0310823.

Article  PubMed  Google Scholar 

de la Fuente C, Rodriguez M, Merino N, et al. Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2023;62(1): 106818.

Article  PubMed  Google Scholar 

Dalfino L, Stufano M, Bavaro DF, et al. Effectiveness of first-line therapy with old and novel antibiotics in ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii: a real life, prospective, observational, single-center study. Antibiotics (Basel). 2023;12(6):1048.

Article  CAS  PubMed  PubMed Central